Climbing Higher: Janice Armbrust’s Glioblastoma Journey at Pacific Neuroscience Institute
**Sponsored Content**
There’s no stopping Janice Armbrust. Discover how her passion for hiking is helping her thrive with glioblastoma.
**Sponsored Content**
There’s no stopping Janice Armbrust. Discover how her passion for hiking is helping her thrive with glioblastoma.
**Sponsored Content**
Learn more about Biodexa’s Phase 1 clinical trial investigating the effectiveness of an approved blood cancer drug in liquid form to treat recurrent glioblastoma (GBM).
From groundbreaking research to new collaborations at a federal level, discover the top three brain tumor news highlights and milestones for the year.
**Sponsored Content**
Learn more about Imvax’s Phase 2b trial studying a personalized, whole tumor-derived immunotherapy in newly diagnosed patients with glioblastoma.
**Sponsored Content**
An acoustic neuroma diagnosis comes with complex treatment decisions. Read why a multidisciplinary care team is crucial for your long-term recovery.
A first-in-class targeted therapy for low-grade glioma could gain FDA approval as early as spring 2024. Here are three things you should know about the emerging drug “vorasidenib.”
On November 17, 2022, results from a phase 3 trial of DCVax-L, an immunotherapy for glioblastoma patients, were published in the Journal of the American Medical Association (JAMA) Oncology.
American Brain Tumor Association
8550 W. Bryn Mawr Ave. Ste 550
Chicago, IL 60631
